Ceapro Inc (CRPOF) 0.4550 $CRPOF
Ceapro Expands License Agreement With University of Alberta for PGX Technology
Marketwired - Wed Feb 11, 7:03AM CST
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"
, a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced an expansion to its agreement with the University of Alberta for the development and commercialization of an innovative drying technology called Pressurized Gas eXpanded Technology (PGX) to include all fields of use, including emerging industrial opportunities. The original agreement was established in April 2014 for the development and commercialization of the PGX technology in select large markets like cosmeceuticals, functional food, nutraceuticals and pharmaceuticals.
CZO.VN: 0.580 (-0.040)
Ceapro Raises an Additional $310,000 Through a Non-Brokered Private Placement
Marketwired - Wed Feb 04, 4:01PM CST
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company", a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it has closed a $310,000 second tranche of its previously announced private placement of eight (
percent unsecured convertible debentures (the "Debentures" due December 31, 2016, with interest payable on June 30 and December 31 of each year.
CZO.VN: 0.580 (-0.040)
Ceapro Raises $650,000 through a Non-Brokered Private Placement
Marketwired - Wed Jan 21, 5:00PM CST
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company", a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it has received conditional TSX-V approval for and has closed a $650,000 first tranche private placement of eight ( percent unsecured convertible debentures (the "Debentures" due December 31, 2016, with interest payable on June 30 and December 31 of each year.
CZO.VN: 0.580 (-0.040)
Ceapro to Present at the Eighth Annual OneMedForum on Tuesday, January 13, 2015
Marketwired - Thu Jan 08, 7:05AM CST
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company", a growth-stage biotechnology company focused on the development and commercialization of active ingredients for health care and cosmetic industries, announced today that its President and Chief Executive Officer, Gilles Gagnon M.Sc., MBA, will be presenting at the Eighth Annual OneMedForum being held January 12 - 13, 2015, at the Marriott Marquis in San Francisco, CA.
CZO.VN: 0.580 (-0.040)
Ceapro Announces Grant of Stock Options
Marketwired - Wed Jan 07, 6:01PM CST
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company", today announced the granting of stock options to its employees, directors, and officers for a total of 950,000 stock options, each with an exercise price of $0.64. Each grant vests in three equal instalments, the first of which vests immediately with the second and third instalments vesting on the first and second anniversaries of the date of grant. Each option is exercisable, once vested, for a period of ten years from the date of grant.
CZO.VN: 0.580 (-0.040)
Ceapro Enters into Financing Agreement with Agriculture Financial Services Corporation
Marketwired - Thu Dec 18, 7:36AM CST
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company", a growth-stage biotechnology company focused on the development and commercialization of active ingredients for health care and cosmetic industries, announced today that it has signed an Offer Letter with Agriculture Financial Services Corporation (AFSC) for a commercial financing of up to $900,000.
CZO.VN: 0.580 (-0.040)
Ceapro Awarded Research Grant from Alberta Innovates Bio Solutions to Develop Novel Formulations for Energy Drink
Marketwired - Thu Dec 04, 7:06AM CST
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company", a growth-stage biotechnology company focused on the development and commercialization of active ingredients for health care and cosmetic industries, announced today that it has been awarded a non-reimbursable grant of $198,000 by Alberta Innovates Bio Solutions (AI Bio) to develop the Company's proprietary Beta Glucan formulation in combination with certain bioactives, for use in an energy drink. The AI Bio grant will support a collaborative research project being conducted with Professor Feral Temelli, Ph.D., at the Department of Agricultural, Food & Nutritional Science at the University of Alberta.
CZO.VN: 0.580 (-0.040)
Ceapro's Research Scientist, Bernhard Seifried, Ph.D., Honored with Scientific Achievement & Innovation Award from BioAlberta
Marketwired - Wed Nov 26, 10:01AM CST
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company", a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Bernhard Seifried, Ph.D., Senior Research Scientist at the Company, was recognized as the recipient of the Achievement Award for Scientific Achievement & Innovation at the BioAlberta 15th Annual General Meeting and Awards Gala in Calgary, Canada on November 25. The BioAlberta Scientific Achievement & Innovation award honors scientists and entrepreneurs who have demonstrated leadership and made significant, extensive and tangible contributions to the Alberta and Canadian life science community.
CZO.VN: 0.580 (-0.040)
Ceapro Appoints World Renowned Health and Disease Management Expert, William W. Li, M.D. to Board of Directors
Marketwired - Thu Nov 20, 7:36AM CST
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company", a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today the Company has appointed international health and disease management expert, William W. Li, M.D., to its Board of Directors.
CZO.VN: 0.580 (-0.040)
Ceapro Inc. Reports Third Quarter 2014 Financial Results
Marketwired - Fri Nov 14, 7:06AM CST
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company", a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today its financial results for the third quarter and nine-months ended September 30, 2014.
CZO.VN: 0.580 (-0.040)
Ceapro Expands License Agreement With University of Alberta for PGX Technology
Marketwired - Wed Feb 11, 7:03AM CST
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"
, a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced an expansion to its agreement with the University of Alberta for the development and commercialization of an innovative drying technology called Pressurized Gas eXpanded Technology (PGX) to include all fields of use, including emerging industrial opportunities. The original agreement was established in April 2014 for the development and commercialization of the PGX technology in select large markets like cosmeceuticals, functional food, nutraceuticals and pharmaceuticals. CZO.VN: 0.580 (-0.040)
Ceapro Raises an Additional $310,000 Through a Non-Brokered Private Placement
Marketwired - Wed Feb 04, 4:01PM CST
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"
, a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it has closed a $310,000 second tranche of its previously announced private placement of eight ( percent unsecured convertible debentures (the "Debentures" due December 31, 2016, with interest payable on June 30 and December 31 of each year. CZO.VN: 0.580 (-0.040)
Ceapro Raises $650,000 through a Non-Brokered Private Placement
Marketwired - Wed Jan 21, 5:00PM CST
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"
, a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it has received conditional TSX-V approval for and has closed a $650,000 first tranche private placement of eight ( percent unsecured convertible debentures (the "Debentures" due December 31, 2016, with interest payable on June 30 and December 31 of each year. CZO.VN: 0.580 (-0.040)
Ceapro to Present at the Eighth Annual OneMedForum on Tuesday, January 13, 2015
Marketwired - Thu Jan 08, 7:05AM CST
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"
, a growth-stage biotechnology company focused on the development and commercialization of active ingredients for health care and cosmetic industries, announced today that its President and Chief Executive Officer, Gilles Gagnon M.Sc., MBA, will be presenting at the Eighth Annual OneMedForum being held January 12 - 13, 2015, at the Marriott Marquis in San Francisco, CA. CZO.VN: 0.580 (-0.040)
Ceapro Announces Grant of Stock Options
Marketwired - Wed Jan 07, 6:01PM CST
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"
, today announced the granting of stock options to its employees, directors, and officers for a total of 950,000 stock options, each with an exercise price of $0.64. Each grant vests in three equal instalments, the first of which vests immediately with the second and third instalments vesting on the first and second anniversaries of the date of grant. Each option is exercisable, once vested, for a period of ten years from the date of grant. CZO.VN: 0.580 (-0.040)
Ceapro Enters into Financing Agreement with Agriculture Financial Services Corporation
Marketwired - Thu Dec 18, 7:36AM CST
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"
, a growth-stage biotechnology company focused on the development and commercialization of active ingredients for health care and cosmetic industries, announced today that it has signed an Offer Letter with Agriculture Financial Services Corporation (AFSC) for a commercial financing of up to $900,000. CZO.VN: 0.580 (-0.040)
Ceapro Awarded Research Grant from Alberta Innovates Bio Solutions to Develop Novel Formulations for Energy Drink
Marketwired - Thu Dec 04, 7:06AM CST
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"
, a growth-stage biotechnology company focused on the development and commercialization of active ingredients for health care and cosmetic industries, announced today that it has been awarded a non-reimbursable grant of $198,000 by Alberta Innovates Bio Solutions (AI Bio) to develop the Company's proprietary Beta Glucan formulation in combination with certain bioactives, for use in an energy drink. The AI Bio grant will support a collaborative research project being conducted with Professor Feral Temelli, Ph.D., at the Department of Agricultural, Food & Nutritional Science at the University of Alberta. CZO.VN: 0.580 (-0.040)
Ceapro's Research Scientist, Bernhard Seifried, Ph.D., Honored with Scientific Achievement & Innovation Award from BioAlberta
Marketwired - Wed Nov 26, 10:01AM CST
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"
, a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Bernhard Seifried, Ph.D., Senior Research Scientist at the Company, was recognized as the recipient of the Achievement Award for Scientific Achievement & Innovation at the BioAlberta 15th Annual General Meeting and Awards Gala in Calgary, Canada on November 25. The BioAlberta Scientific Achievement & Innovation award honors scientists and entrepreneurs who have demonstrated leadership and made significant, extensive and tangible contributions to the Alberta and Canadian life science community. CZO.VN: 0.580 (-0.040)
Ceapro Appoints World Renowned Health and Disease Management Expert, William W. Li, M.D. to Board of Directors
Marketwired - Thu Nov 20, 7:36AM CST
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"
, a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today the Company has appointed international health and disease management expert, William W. Li, M.D., to its Board of Directors. CZO.VN: 0.580 (-0.040)
Ceapro Inc. Reports Third Quarter 2014 Financial Results
Marketwired - Fri Nov 14, 7:06AM CST
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"
, a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today its financial results for the third quarter and nine-months ended September 30, 2014. CZO.VN: 0.580 (-0.040)
